Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant

por Cao, Xing-yu, Zhang, Jian-ping, Zhao, Yan-li, Xiong, Min, Zhou, Jia-rui, Lu, Yue, Sun, Rui-juan, Wei, Zhi-jie, Liu, De-yan, Zhang, Xian, Yang, Jun-fang, Lu, Peihua
Publicado 2023

Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemother...

por Zhao, Yan-Li, Liu, De-Yan, Sun, Rui-Juan, Zhang, Jian-Ping, Zhou, Jia-Rui, Wei, Zhi-Jie, Xiong, Min, Cao, Xing-Yu, Lu, Yue, Yang, Jun-fang, Zhang, Xian, Lu, Dao-Pei, Lu, Peihua
Publicado 2021

Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation...

por Lu, Yue, Zhang, Jian-Ping, Zhao, Yan-Li, Xiong, Min, Sun, Rui-Juan, Cao, Xing-Yu, Wei, Zhi-Jie, Zhou, Jia-Rui, Liu, De-Yan, Yang, Jun-Fang, Zhang, Xian, Lu, Dao-Pei, Lu, Peihua
Publicado 2023

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML

por Cao, Xing-yu, Chen, Jia-qi, Wang, Hui, Ma, Wei, Liu, Wei-wei, Zhang, Fang-fang, Xue, Song, Dong, Lei, Liu, Ting, Zhao, Xiao-zhen, Liu, Chan-chan, Xu, Xin, He, Yang, Wang, Lei, Wang, Jian-ling
Publicado 2023